Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission

J. Hurnakova, H. Hulejova, J. Zavada, M. Komarc, P. Hanova, M. Klein, H. Mann, O. Sleglova, M. Olejarova, S. Forejtova, O. Ruzickova, J. Vencovsky, K. Pavelka, L. Senolt,

. 2016 ; 11 (11) : e0165498. [pub] 20161110

Language English Country United States

Document type Journal Article

OBJECTIVE: Clinical remission in some patients with rheumatoid arthritis (RA) may be associated with ongoing synovial inflammation that is not always detectable on clinical examination or reflected by laboratory tests but can be visualized by musculoskeletal ultrasound. The goal of our study was to determine the levels of serum calprotectin, a major leukocyte protein, in patients with RA in clinical remission and to investigate the ability of serum calprotectin levels to distinguish patients in ultrasound-defined remission from those with residual ultrasound subclinical inflammation. METHODS: Seventy RA patients in clinical remission underwent clinical and ultrasound examination. Ultrasound examination was performed according to the German US7 score. Ultrasound remission was defined as grey scale (GS) range 0-1 and power Doppler (PD) range 0. The levels of serum calprotectin and C-reactive protein (CRP) were determined. The discriminatory capacity of calprotectin and CRP in detecting residual ultrasound inflammation was assessed using ROC curves. RESULTS: The total number of patients fulfilling the DAS28-ESR, DAS28-CRP, SDAI and CDAI remission criteria was 58, 67, 32 and 31, respectively. Residual synovial inflammation was found in 58-67% of the patients who fulfilled at least one set of clinical remission criteria. Calprotectin levels were significantly higher in patients with residual synovial inflammation than in those with ultrasound-defined remission (mean 2.5±1.3 vs. 1.7±0.8 μg/mL, p<0.005). Using ultrasound-defined remission criteria, calprotectin had an AUC of 0.692, p<0.05 using DAS28-ESR remission criteria and an AUC of 0.712, p<0.005 using DAS28-CRP remission criteria. Calprotectin correctly distinguished ultrasound remission from subclinical activity in 70% of patients. CRP (AUC DAS28-ESR = 0.494, p = NS; AUC DAS28-CRP = 0.498, p = NS) had lower and insignificant discriminatory capacity. CONCLUSION: The present study demonstrates the potential of calprotectin to distinguish RA patients in both clinical and ultrasound-defined remission from patients in clinical remission but with residual subclinical disease activity.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023512
003      
CZ-PrNML
005      
20170720122250.0
007      
ta
008      
170720s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0165498 $2 doi
035    __
$a (PubMed)27832086
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hurnakova, Jana $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
245    10
$a Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission / $c J. Hurnakova, H. Hulejova, J. Zavada, M. Komarc, P. Hanova, M. Klein, H. Mann, O. Sleglova, M. Olejarova, S. Forejtova, O. Ruzickova, J. Vencovsky, K. Pavelka, L. Senolt,
520    9_
$a OBJECTIVE: Clinical remission in some patients with rheumatoid arthritis (RA) may be associated with ongoing synovial inflammation that is not always detectable on clinical examination or reflected by laboratory tests but can be visualized by musculoskeletal ultrasound. The goal of our study was to determine the levels of serum calprotectin, a major leukocyte protein, in patients with RA in clinical remission and to investigate the ability of serum calprotectin levels to distinguish patients in ultrasound-defined remission from those with residual ultrasound subclinical inflammation. METHODS: Seventy RA patients in clinical remission underwent clinical and ultrasound examination. Ultrasound examination was performed according to the German US7 score. Ultrasound remission was defined as grey scale (GS) range 0-1 and power Doppler (PD) range 0. The levels of serum calprotectin and C-reactive protein (CRP) were determined. The discriminatory capacity of calprotectin and CRP in detecting residual ultrasound inflammation was assessed using ROC curves. RESULTS: The total number of patients fulfilling the DAS28-ESR, DAS28-CRP, SDAI and CDAI remission criteria was 58, 67, 32 and 31, respectively. Residual synovial inflammation was found in 58-67% of the patients who fulfilled at least one set of clinical remission criteria. Calprotectin levels were significantly higher in patients with residual synovial inflammation than in those with ultrasound-defined remission (mean 2.5±1.3 vs. 1.7±0.8 μg/mL, p<0.005). Using ultrasound-defined remission criteria, calprotectin had an AUC of 0.692, p<0.05 using DAS28-ESR remission criteria and an AUC of 0.712, p<0.005 using DAS28-CRP remission criteria. Calprotectin correctly distinguished ultrasound remission from subclinical activity in 70% of patients. CRP (AUC DAS28-ESR = 0.494, p = NS; AUC DAS28-CRP = 0.498, p = NS) had lower and insignificant discriminatory capacity. CONCLUSION: The present study demonstrates the potential of calprotectin to distinguish RA patients in both clinical and ultrasound-defined remission from patients in clinical remission but with residual subclinical disease activity.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a revmatoidní artritida $x krev $x diagnostické zobrazování $7 D001172
650    _2
$a C-reaktivní protein $x analýza $7 D002097
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a zánět $x krev $x diagnostické zobrazování $7 D007249
650    _2
$a leukocytární L1-antigenní komplex $x krev $7 D039841
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a reziduální nádor $7 D018365
650    _2
$a ultrasonografie $7 D014463
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hulejova, Hana $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Zavada, Jakub $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Komarc, Martin $u Department of Methodology, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic.
700    1_
$a Hanova, Petra $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Klein, Martin $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Mann, Herman $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Sleglova, Olga $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Olejarova, Marta $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Forejtova, Sarka $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Ruzickova, Olga $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Vencovsky, Jiri $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Pavelka, Karel $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Senolt, Ladislav $u Institute of Rheumatology, Prague, Czech Republic. Rheumatology Department, First Faculty of Medicine, Charles University, Prague, Czech Republic.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 11, č. 11 (2016), s. e0165498
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27832086 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170720122743 $b ABA008
999    __
$a ok $b bmc $g 1239193 $s 984425
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 11 $c 11 $d e0165498 $e 20161110 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20170720

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...